Skip to main content
    C

    Collegium Pharmaceutical Inc (COLL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $25.43
    +0.11 (+0.43%)

    Market Cap: $786.83M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Collegium Pharmaceutical Inc (COLL) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Collegium Pharmaceutical (COLL) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Collegium Pharmaceutical reported EPS of $1.71, above the $1.53 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    68%(27/40)
    Avg Surprise
    +11.03%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.03
    Range$1.86 - $2.15
    10 analysts
    Revenue Consensus
    $226.07M
    Range$212.07M - $235.52M
    9 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.62
    Range$1.25 - $1.84
    5 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$1.53+5.6%
    60d ago$1.54+5.1%
    30d ago$1.56+3.6%
    7d ago$1.56+3.9%
    Current$1.62
    Revenue Consensus
    $200.74M
    Range$185.10M - $206.41M
    4 analysts

    Next Report

    COLL has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 9.7% above the $1.85 reported for the quarter ended Dec 31, 2025.

    COLL Earnings Call

    The latest COLL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, COLL beat 27 and missed 13. Revenue for the quarter ended Sep 30, 2026 was $216.34M, up 3.3% from $209.36M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.71$1.53N/A+11.76%Beat-24.0%71 up, 2 downNov 5, 2026$216.34M
    Jun 30, 2026$1.57$1.48N/A+6.08%Beat+6.8%22 up, 3 downAug 6, 2026$199.88M
    Mar 31, 2026$1.76$1.52$1.27 - $1.74+15.79%Beat+18.1%51 up, 2 downMay 7, 2026$193.52M
    Dec 31, 2025$1.85$2.01$1.93 - $2.26-7.96%Miss+4.5%51 up, 0 downFeb 26, 2026$205.45M
    Sep 30, 2025$2.25$1.86$1.79 - $1.95+20.97%Beat+39.8%40 up, 2 downNov 6, 2025$209.36M
    Jun 30, 2025$1.47$1.43N/A+2.80%Beat-9.3%40 up, 1 downAug 7, 2025$188.00M
    Mar 31, 2025$1.49$1.45$1.34 - $1.66+2.76%Beat+2.8%40 up, 0 downMay 8, 2025$177.76M
    Dec 31, 2024$1.77$1.54$1.49 - $1.63+15.12%Beat+12.0%42 up, 0 downFeb 27, 2025$181.95M
    Sep 30, 2024$1.61$1.59$1.45 - $1.84+1.26%Beat+20.1%42 up, 0 downNov 7, 2024$159.30M
    Jun 30, 2024$1.62$1.49$1.37 - $1.62+8.72%Beat+28.6%44 up, 0 downAug 8, 2024$145.28M
    Mar 31, 2024$1.45$1.47N/A-1.36%Miss+9.8%30 up, 1 downMay 9, 2024$144.92M
    Dec 31, 2023$1.58$1.25N/A+26.40%BeatN/A20 up, 1 downFeb 22, 2024$149.75M
    Sep 30, 2023$1.34$1.24N/A+8.06%Beat+21.8%30 up, 1 downNov 7, 2023$136.71M
    Jun 30, 2023$1.26$1.22N/A+3.28%Beat+4.1%40 up, 1 downAug 3, 2023$135.55M
    Mar 31, 2023$1.32$1.51N/A-12.58%Miss+45.1%51 up, 0 downMay 4, 2023$144.77M
    Dec 31, 2022-$0.21-$0.14-$0.80 - $0.30-50.00%MissN/A44 up, 0 downFeb 23, 2023$129.62M
    Sep 30, 2022$1.10$1.38N/A-20.29%Miss+41.0%40 up, 1 downNov 3, 2022$127.01M
    Jun 30, 2022$1.21$1.44$1.08 - $1.97-15.97%Miss+49.4%70 up, 1 downAug 4, 2022$123.55M
    Mar 31, 2022$0.91$0.90$0.44 - $1.04+1.11%Beat-5.2%60 up, 0 downMay 10, 2022$83.75M
    Dec 31, 2021-$0.51$1.04$0.96 - $1.11-149.04%Miss-355.0%71 up, 1 downFeb 24, 2022$27.36M
    Sep 30, 2021$0.78$0.96$0.90 - $1.03-18.75%Miss-24.3%6N/ANov 4, 2021$78.84M
    Jun 30, 2021$0.81$0.95N/A-14.74%Miss-14.7%4N/AAug 5, 2021$82.94M
    Mar 31, 2021$0.96$1.00N/A-4.00%Miss+9500.0%4N/AMay 6, 2021$87.72M
    Dec 31, 2020$0.20$0.39N/A-48.72%Miss+25.0%5N/AFeb 25, 2021$76.27M
    Sep 30, 2020$1.03$0.90N/A+14.44%Beat+1960.0%5N/ANov 5, 2020$79.18M
    Jun 30, 2020$0.95$0.86N/A+10.47%Beat+955.6%5N/AAug 5, 2020$78.06M
    Mar 31, 2020$0.01$0.41$0.08 - $0.64-97.56%MissN/A6N/AMay 7, 2020$76.51M
    Dec 31, 2019$0.16$0.10-$0.25 - $0.22+60.00%Beat-40.7%6N/AFeb 27, 2020$74.20M
    Sep 30, 2019$0.05$0.03N/A+66.67%BeatN/A6N/ANov 6, 2019$72.94M
    Jun 30, 2019$0.09-$0.04N/A+325.00%BeatN/A6N/AAug 7, 2019$75.04M
    Mar 31, 2019-$0.05-$0.15-$0.40 - -$0.12+66.67%BeatN/A5N/AMay 8, 2019$74.52M
    Dec 31, 2018$0.27-$0.35-$0.50 - -$0.23+177.14%BeatN/A5N/AFeb 27, 2019$73.43M
    Sep 30, 2018-$0.25-$0.12N/A-108.33%MissN/A5N/ANov 8, 2018$70.18M
    Jun 30, 2018-$0.15-$0.33-$0.67 - -$0.31+54.55%BeatN/A6N/AAug 8, 2018$73.06M
    Mar 31, 2018-$0.57-$0.65-$0.73 - -$0.23+12.31%BeatN/A5N/AMay 9, 2018$63.75M
    Dec 31, 2017-$0.54-$0.57-$0.67 - -$0.49+5.26%BeatN/A6N/AMar 7, 2018$10.79M
    Sep 30, 2017-$0.45-$0.73-$0.80 - -$0.67+38.36%BeatN/A6N/ANov 8, 2017$11.95M
    Jun 30, 2017-$0.72-$0.80-$0.85 - -$0.76+10.00%BeatN/A5N/AAug 9, 2017$3.56M
    Mar 31, 2017-$0.79-$1.00N/A+21.00%BeatN/AN/AN/AMay 10, 2017$2.17M
    Dec 31, 2016-$1.02-$1.07N/A+4.67%BeatN/AN/AN/AMar 9, 2017$1.30M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $7.06, up 9.5% from the year before. It was -$3.88 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$7.06+9.5%
    Dec 31, 2024$6.45+17.3%
    Dec 31, 2023$5.50+82.7%
    Dec 31, 2022$3.01+47.5%
    Dec 31, 2021$2.04-6.8%
    Dec 31, 2020$2.19+776.0%
    Dec 31, 2019$0.25N/A
    Dec 31, 2018-$0.70N/A
    Dec 31, 2017-$2.50N/A
    Dec 31, 2016-$3.88N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,01710
    2026Q2Jun 30, 20264,3658
    2026Q1Mar 31, 20265,81410
    2025Q4Dec 31, 20255,4348
    2025Q3Sep 30, 20254,57010
    2025Q2Jun 30, 20254,6038
    2025Q1Mar 31, 20254,8988
    2024Q4Dec 31, 20244,7197

    2026Q3 Earnings Call

    Opening remarks

    Ian Karp Head of Investor Relations Thank you. You may begin. Great. Thanks, Maria, and welcome to Collegium Pharmaceutical's Third Quarter 2026 Earnings Conference Call. I am joined today by Vikram Karnani, our President and Chief Executive Officer, and Colleen Tupper, our Chief Financial Officer. Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 2000. We are cautioned that such forward-looking statements involve risks and uncertainties, detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website. And with that, I will now turn the call over to our President and CEO, Vikram Karnani.

    Vikram Karnani President and CEO Thank you, Ian. Good morning, everyone, and thank you for joining our third quarter 2026 earnings call. Collegium is a dynamic commercial-stage biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions. Our success is built upon our proven ability to acquire, integrate, and grow differentiated medicines while creating long-term shareholder value. This strategy has established a portfolio of six differentiated medicines, reflecting the significant evolution our company has undertaken over the past several years. ADHD has become our lead growth driver, accounting for more than 36% of total revenue, up from just 19% last year. With Jornay PM and Azstarys, we have two complementary medicines supported by an expanding commercial platform to drive future growth. Meanwhile, our pain portfolio continues to generate robust cash flows, providing the financial flexibility to invest in our ADHD portfolio and further diversify our business. The team at Collegium remains focused, invigorated, and committed to making a meaningful difference in the lives of patients and creating long-term value for our shareholders. We delivered record quarterly net revenue of $216.3 million, up 3% year over year, driven by growth in ADHD during the important back-to-school season. Key achievements this quarter included Jornay PM prescriptions growing by 16%, generating a record $59.5 million in net revenue, up 24% year over year. Jornay PM prescribers also reached another all-time high, with nearly 33,000 healthcare providers writing Jornay PM prescriptions in the quarter, up 19% over Q3 of last year. Our investments in Jornay PM are translating into broader prescriber and continued prescription growth. Azstarys generated $26.5 million in net revenue during its first full quarter under our ownership.

    Frequently Asked Questions About COLL

    When is Collegium Pharmaceutical's next earnings date?

    Collegium Pharmaceutical's next earnings report is expected for Feb 24, 2027.

    Did COLL beat earnings estimates last quarter?

    Yes. Collegium Pharmaceutical reported EPS of $1.71 for the quarter ended Sep 30, 2026, above the $1.53 estimate, a 11.76% surprise.

    What EPS do analysts expect from COLL next quarter?

    The consensus EPS estimate for Collegium Pharmaceutical for the quarter ending Dec 31, 2026 is $2.03 from 10 analysts, with estimates from $1.86 to $2.15.

    How often does COLL beat earnings estimates?

    Collegium Pharmaceutical beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +8.42%.